Study Name Principal Investigator
A Phase 1 / 2, Open-Label, Multiple Ascending Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of AGEN2034 in Subjects With Metastatic or Locally Advanced Solid Tumors, With Expansion to Second-Line Cervical Cancer Ghamande, Sharad
ADXS001-04: Phase 1-2 Study of MEDI4736 Alone or In Combination with ADXS11-001 In Recurrent/Persistent or Metastatic Cervical or HPV+ Head & Neck Cancer Ghamande, Sharad
C-145-04: A Phase 2, Multicenter Study to Evaluate the Efficacy and Safety Using Autologous Tumor Infiltrating Lymphocytes (LN-145) in Patients with Recurrent, Metastatic or Persistent Cervical Carcinoma Ghamande, Sharad
Cervical Diverticulum Prospective, Multi-Institutional Study Proposal Postma, Gregory
GCT1015-05/GOG 3024: A Phase 1b/2 Open-Label Trial of Tisotumab Vedotin (HuMax® -TF -ADC) in Combination with Other Agents in Subjects with Recurrent or Stage IVB Cervical Cancer Ghamande, Sharad
Georgetown STUDY00003849: A phase II trial of combination therapy of pembrolizumab and lenvatinib in patients with locally advanced or metastatic cervical cancer Ghamande, Sharad
Implementing HPV DNA Self-Collection to Increase Rates of Cervical Cancer Screening In Transgender Men Theisen, John
MS200647_0046 Safety Study of Bintrafusp alfa in Combination with Other Anti-cancer Therapies in Participants with Locally Advanced or Advanced Cervical Cancer Ghamande, Sharad
SGNTV-003/GOG 3057: A Randomized, Open-Label, Phase 3 Trial of Tisotumab Vedotin vs Investigator’s Choice Chemotherapy in Second- or Third-Line Recurrent or Metastatic Cervical Cancer Ghamande, Sharad